<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: This study examined how differences in the BMI distribution of type 2 diabetic case subjects affected genome-wide patterns of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> association and considered the implications for the etiological <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: We reanalyzed data from the Wellcome Trust Case Control Consortium genome-wide association scan (1,924 case subjects, 2,938 control subjects: 393,453 single-nucleotide polymorphisms [SNPs]) after stratifying case subjects (into "<z:mp ids='MP_0001261'>obese</z:mp>" and "nonobese") according to median BMI (30.2 kg/m(2)) </plain></SENT>
<SENT sid="2" pm="."><plain>Replication of signals in which alternative case-ascertainment strategies generated marked effect size <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> association signal was sought in additional samples </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: In the "<z:mp ids='MP_0001261'>obese</z:mp>-type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>" scan, FTO variants had the strongest type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> effect (rs8050136: relative risk [RR] 1.49 [95% CI 1.34-1.66], P = 1.3 x 10(-13)), with only weak evidence for TCF7L2 (rs7901695 RR 1.21 [1.09-1.35], P = 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>This situation was reversed in the "nonobese" scan, with FTO association undetectable (RR 1.07 [0.97-1.19], P = 0.19) and TCF7L2 predominant (RR 1.53 [1.37-1.71], P = 1.3 x 10(-14)) </plain></SENT>
<SENT sid="5" pm="."><plain>These patterns, confirmed by replication, generated strong combined evidence for between-stratum effect size <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> (FTO: P(DIFF) = 1.4 x 10(-7); TCF7L2: P(DIFF) = 4.0 x 10(-6)) </plain></SENT>
<SENT sid="6" pm="."><plain>Other signals displaying evidence of effect size <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in the genome-wide analyses (on chromosomes 3, 12, 15, and 18) did not replicate </plain></SENT>
<SENT sid="7" pm="."><plain>Analysis of the current list of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> susceptibility variants revealed nominal evidence for effect size <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> for the SLC30A8 locus alone (RR(<z:mp ids='MP_0001261'>obese</z:mp>) 1.08 [1.01-1.15]; RR(nonobese) 1.18 [1.10-1.27]: P(DIFF) = 0.04) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: This study demonstrates the impact of differences in case ascertainment on the power to detect and replicate genetic associations in genome-wide association studies </plain></SENT>
<SENT sid="9" pm="."><plain>These data reinforce the notion that there is substantial etiological <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> within type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>